Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL222541 | 1.00 | CA1 (0.30) | CA1CA2CA9CA12GLA | |
| Hydrochloric Acid SCHEMBL5107414 | 0.95 | CA1 (0.30) | CA1CA2CA9CA12GLA | |
| SCHEMBL197099 | 0.95 | CA1 (0.33) | CA1CA2CA9CA12GLA | |
| Hydrochloric Acid SCHEMBL7165412 | 0.92 | CA1 (0.32) | CA1CA2CA9CA12GLA | |
| SCHEMBL1398394 | 0.92 | CA1 (0.32) | CA1CA2CA9CA12GLA | |
| SCHEMBL7769634 | 0.92 | CA1 (0.32) | CA1CA2CA9CA12GLA | |
| Hydrochloric Acid SCHEMBL7165413 | 0.92 | CA1 (0.32) | CA1CA2CA9CA12GLA | |
| Bromide SCHEMBL5510644 | 0.90 | CA1 (0.30) | CA1CA2CA9CA12GLA | |
| Hydrochloric Acid SCHEMBL5107617 | 0.90 | CA1 (0.30) | CA1CA2CA9CA12GLA | |
| Hydrochloric Acid SCHEMBL222540 | 0.90 | CA1 (0.30) | CA1CA2CA9CA12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7048292-A | — | — | None | — | — | JP | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1572606-A4 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENT CO (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7205427-B2 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | BOULDER SCIENTIFIC COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1572606-A2 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040267072-A1 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | ANTARES CAPITAL LP, AS AGENT | 2004-12-30 | — | — | US | disclosed |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| US-6696470-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003101601-A2 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
| US-5314976-A | Heterocyclic polymers | NATIONAL SCIENCE COUNCIL (TW) | 1994-05-24 | — | — | US | disclosed |
| EP-0589491-A1 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5292770-A | Butenoic acid derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5272234-A | Photo-responsive conductive polymers and the processes of making the same | NATIONAL SCIENCE COUNCIL (TW) | 1993-12-21 | — | — | US | disclosed |
| EP-0535635-A1 | Tolane derivative, liquid crystal composition containing the derivative, and liquid crystal display device using the composition | SEIKO EPSON CORPORATION (JP) | 1993-04-07 | — | — | EP | disclosed |
| US-5177089-A | Antiischemic agent, vasodilator | EISAI CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| US-5166188-A | Cardiovascular disorders, antiischemic agents | EISAI CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5047417-A | Butenoic or propenoic acid derivatives | EISAI CO. LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0399358-A2 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1990-11-28 | — | — | EP | disclosed |
| EP-0344577-A2 | Butenoic or propenoic acid derivatives | Eisai Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267072-A1 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | DDT, DUOX2, DYRK4 | CA1 2083/4885CA2 1916/4885CA9 1124/4885 |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, FCGR2A, OGFR | CA1 2690/4885CA2 1869/4885CA9 4077/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | CA1 3796/4885CA2 3198/4885CA9 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.